1346675-25-9

Upstream product

• 1346674-21-2 ethyl 1-(cyanomethyl)-5,5-dimethyl-1,4,5,6-tetrahydrocyclo-penta[b]pyrrole-2-carboxylate 
• 1346674-20-1 ethyl 5,5-dimethyl-1,4,5,6-tetrahydrocyclopenta[b]pyrrole-2-carboxylate 
• 1346674-19-8 (E)-ethyl 3-(2-Chloro-4,4-dimethylcyclopent-1-enyl)acrylate 
• 1346672-63-6 2-chloro-4,4- dimethylcyclopent-1-ene-1-carbaldehyde 
• 20500-49-6 3,3-dimethylcyclopentanone 
• 2758-18-1 3-Methyl-2-cyclopenten-1-one 
• 1346674-61-0 2-bromo-4-fluoro-6-(9-oxo-4,4-dimethyl-1,10diazatricyclo[6.4.0.0^2,6]dodeca-2⁽⁶⁾,7-dien-10-yl)benzyl acetate 
• 73183-34-3 bis(pinacol)diborane 
• 1346674-62-1 2,6-dibromo-4-fluorobenzyl acetate 
• 62720-29-0 1,3-dibromo-5-fluoro-2-iodobenzene 
• 938467-02-8 2,6-dibromo-4-fluorobenzaldehyde 
• 1346674-69-8 (2,6-dibromo-4-fluorophenyl)methanol 

Relevant academic research and scientific papers

ALKYLATED PIPERAZINE COMPOUNDS

Alkylated piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

BICYCLIC PIPERAZINE COMPOUNDS

Bicyclic piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE

Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.